ScreenshotAthersys, Inc. (ATHX) will release its first quarter 2014 financial results at approximately 4:00 PM (Eastern Time) on Thursday, May 8, 2014, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Read more

Date

12zsTargeted Medical Pharma (TRGM), today announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism, for the exclusive distribution of the company’s amino acid based products to physicians and pharmacies throughout the Middle East.

The Agreement provides ATL with a limited exclusive license for the marketing and … Read more

clrxCollabRx, Inc. (CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx’s Genetic Variant Annotation (GVA) Service(TM) in connection with Affymetrix’ OncoScan(TM) FFPE Assay Kit and CytoScan(R) Cytogenetics Suite … Read more

ScreenHunter_186-Mar.-12-11.04Champions Oncology Treating cancer has long been a trial and error process for doctors, but Champions Oncology is hoping to take the guess work out of choosing the right therapy through the use of its mouse avatars. The company engrafts a patient’s tumor in mice to determine what drugs are most effective. We spoke to Joel Ackerman, CEO of Champions Oncology, about the personalization of … Read more

admin-ajaxHarvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has hired Saverio La Francesca, MD, a veteran cardiothoracic surgeon and leading organ transplant physician, as the Company’s first Chief Medical Officer, effective April 14.

Dr. La Francesca has a unique combination of experience that features more than 25 years of academic Read more

clrxCollabRx, Inc. (CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx’s Genetic Variant Annotation (GVA) Service(TM) in connection with Affymetrix’ OncoScan(TM) FFPE Assay Kit and CytoScan(R) Cytogenetics Suite for analysis of gene copy number … Read more

cescaCesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced the restructuring of its sales, marketing and technical support organization and the appointment of Tim Lee as Director of International Sales. The restructuring is aimed at further strengthening its cord blood business and new point of care and clinical commercial programs by providing more dedicated resource leadership to each discipline.

The … Read more

admin-ajaxHarvard Apparatus Regenerative Technology, Inc.HART +5.79% , a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that a research team led by Paolo Macchiarini, MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by HART. Dr. Macchiarini has previously overseen several successful regenerated trachea transplants … Read more

protea_resize_logoProtea Biosciences Group, Inc. (OTCQB:PRGB) announced today that the company’s shares of common stock have commenced trading on the OTCQB marketplace of the OTC Markets Group Inc. under the ticker symbol PRGB.

“The commencement of trading represents an important milestone for our company,” stated Steve Turner, Chief Executive Officer at Protea. “We anticipate that the initiation of trading will help us broaden our … Read more

20Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Revenue related to the Company’s license and commercialization … Read more